Drug release and kinetic study of tamoxifen citrate conjugated with magnetite nanoparticle for drug delivery application

Breast cancer is affecting about 23 % of all cancers diagnosed in women. So, it is crucial to develop the treatment for breast cancer patient. Tamoxifen (TAM) has been used for treating estrogen receptor (ER)-positive breast cancer however TAM suffer from non-specific delivery to the breast cancer....

Full description

Bibliographic Details
Main Authors: Albert, Emmellie Laura, Shirosaki, Yuki, Che Abdullah, Che Azurahanim
Format: Article
Language:English
Published: Integrated Publishing Association 2018
Online Access:http://psasir.upm.edu.my/id/eprint/72339/
http://psasir.upm.edu.my/id/eprint/72339/1/Drug%20release%20and%20kinetic%20study%20of%20tamoxifen%20citrate%20conjugated%20with%20magnetite%20nanoparticle%20for%20drug%20delivery%20application%20.pdf
Description
Summary:Breast cancer is affecting about 23 % of all cancers diagnosed in women. So, it is crucial to develop the treatment for breast cancer patient. Tamoxifen (TAM) has been used for treating estrogen receptor (ER)-positive breast cancer however TAM suffer from non-specific delivery to the breast cancer. TAM was introduce to magnetite nanoparticle (MNP) to increase tissue selectivity using Poly (d,l-lactice-co-glycolide acid) (PLGA-TAM-OAMNP) via oil in water emulsion and evaporation process. It was discovered that the size of the modified nanoparticle is 384 ± 17 nm while also maintaining its superparamagnetic nature. The percentage of drug loading and entrapment efficiency of TAM inside the PLGA-TAMOAMNP is around 6% and 80% respectively. Then, drug release was conducted for the next 96 hours releasing about 90% of the drug. The in vitro drug release was due to autocatalysis of PLGA.